Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more
Esperion Therapeutics Inc (ESPR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.009x
Based on the latest financial reports, Esperion Therapeutics Inc (ESPR) has a cash flow conversion efficiency ratio of 0.009x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.29 Million) by net assets ($-451.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Esperion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Esperion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Esperion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Esperion Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ulker Biskuvi Sanayi AS
IS:ULKER
|
0.050x |
|
Systemair AB
ST:SYSR
|
0.056x |
|
ViTrox Corporation Bhd
KLSE:0097
|
-0.023x |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
0.028x |
|
Altarea SCA
PINK:ATRRF
|
0.170x |
|
Fujian Yuanli Active Carbon Co Ltd
SHE:300174
|
0.018x |
|
Borusan Yatirim ve Pazarlama AS
IS:BRYAT
|
-0.001x |
|
Italmobiliare S.p.A.
LSE:0RP4
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Esperion Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Esperion Therapeutics Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-388.72 Million | $-23.65 Million | 0.061x | -79.57% |
| 2023-12-31 | $-454.99 Million | $-135.49 Million | 0.298x | -44.85% |
| 2022-12-31 | $-323.78 Million | $-174.83 Million | 0.540x | -59.69% |
| 2021-12-31 | $-196.94 Million | $-263.81 Million | 1.340x | +51.18% |
| 2020-12-31 | $-96.13 Million | $-85.18 Million | 0.886x | +125.13% |
| 2019-12-31 | $19.95 Million | $-70.34 Million | -3.526x | -87.68% |
| 2018-12-31 | $79.12 Million | $-148.64 Million | -1.879x | -250.11% |
| 2017-12-31 | $244.69 Million | $-131.30 Million | -0.537x | -157.01% |
| 2016-12-31 | $228.60 Million | $-47.73 Million | -0.209x | -57.19% |
| 2015-12-31 | $287.26 Million | $-38.16 Million | -0.133x | +44.60% |
| 2014-12-31 | $133.55 Million | $-32.02 Million | -0.240x | +1.93% |
| 2013-12-31 | $74.09 Million | $-18.11 Million | -0.244x | -139.33% |
| 2012-12-31 | $-17.39 Million | $-10.81 Million | 0.622x | -58.49% |
| 2011-12-31 | $-6.06 Million | $-9.07 Million | 1.497x | +318.37% |
| 2002-12-31 | $38.74 Million | $-26.56 Million | -0.686x | -100.26% |
| 2001-12-31 | $66.50 Million | $-22.77 Million | -0.342x | -29.08% |
| 2000-12-31 | $67.69 Million | $-17.95 Million | -0.265x | +90.49% |
| 1999-12-31 | $2.81 Million | $-7.85 Million | -2.790x | -- |